BACKGROUND: Ampullary adenocarcinoma is a rare malignancy associated with a relatively favorable prognosis. Given high survival rates in stage I patients reported in small series with surgery alone, adjuvant chemoradiotherapy (CRT) has traditionally been recommended only for patients with high risk disease. Recent population-based data have demonstrated inferior outcomes to previous series. We examined disease-related outcomes for stage I tumors treated with pancreaticoduodenectomy, with and without CRT. METHODS: All patients with stage I ampullary adenocarcinoma treated from 1976 to 2011 at Duke University were reviewed. Disease-related endpoints including local control (LC), metastasis-free survival (MFS), disease-free survival (DFS) and overall survival (OS) were analyzed using the Kaplan-Meier method. RESULTS: Forty-four patients were included in this study. Thirty-one patients underwent surgery alone, while 13 also received adjuvant CRT. Five-year LC, MFS, DFS and OS for patients treated with surgery only and surgery with CRT were 56% and 83% (P=0.13), 67% and 83% (P=0.31), 56% and 83% (P=0.13), and 53% and 68% (P=0.09), respectively. CONCLUSIONS: The prognosis for patients diagnosed with stage I ampullary adenocarcinoma may not be as favorable as previously described. Our data suggests a possible benefit of adjuvant CRT delivery.
BACKGROUND:Ampullary adenocarcinoma is a rare malignancy associated with a relatively favorable prognosis. Given high survival rates in stage I patients reported in small series with surgery alone, adjuvant chemoradiotherapy (CRT) has traditionally been recommended only for patients with high risk disease. Recent population-based data have demonstrated inferior outcomes to previous series. We examined disease-related outcomes for stage I tumors treated with pancreaticoduodenectomy, with and without CRT. METHODS: All patients with stage I ampullary adenocarcinoma treated from 1976 to 2011 at Duke University were reviewed. Disease-related endpoints including local control (LC), metastasis-free survival (MFS), disease-free survival (DFS) and overall survival (OS) were analyzed using the Kaplan-Meier method. RESULTS: Forty-four patients were included in this study. Thirty-one patients underwent surgery alone, while 13 also received adjuvant CRT. Five-year LC, MFS, DFS and OS for patients treated with surgery only and surgery with CRT were 56% and 83% (P=0.13), 67% and 83% (P=0.31), 56% and 83% (P=0.13), and 53% and 68% (P=0.09), respectively. CONCLUSIONS: The prognosis for patients diagnosed with stage I ampullary adenocarcinoma may not be as favorable as previously described. Our data suggests a possible benefit of adjuvant CRT delivery.
Entities:
Keywords:
Ampulla of Vater; adjuvant therapy; patterns of failure
Authors: Jean L Wright; Sujata M Patil; Larissa K F Temple; Bruce D Minsky; Leonard B Saltz; Karyn A Goodman Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-29 Impact factor: 7.038
Authors: M A Talamini; R C Moesinger; H A Pitt; T A Sohn; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron Journal: Ann Surg Date: 1997-05 Impact factor: 12.969
Authors: Manisha Palta; Pretesh Patel; Gloria Broadwater; Christopher Willett; Joseph Pepek; Douglas Tyler; S Yousuf Zafar; Hope Uronis; Herbert Hurwitz; Rebekah White; Brian Czito Journal: Ann Surg Oncol Date: 2011-11-02 Impact factor: 5.344
Authors: Sunil Krishnan; Vishal Rana; Douglas B Evans; Gauri Varadhachary; Prajnan Das; Sumita Bhatia; Marc E Delclos; Nora A Janjan; Robert A Wolff; Christopher H Crane; Peter W Pisters Journal: Int J Radiat Oncol Biol Phys Date: 2007-11-05 Impact factor: 7.038
Authors: Jennifer L Gnerlich; Samuel R Luka; Anjali D Deshpande; Bernard J Dubray; Joshua S Weir; Danielle H Carpenter; Elizabeth M Brunt; Steven M Strasberg; William G Hawkins; David C Linehan Journal: Arch Surg Date: 2012-08